Processa Pharmaceuticals, Inc. has filed a registration statement with the Securities and Exchange Commission (SEC) on May 21, 2024, for a proposed public offering of its common stock. The company, incorporated in Delaware and based in Hanover, Maryland, plans to offer up to $2,400,000 of its common stock through A.G.P./Alliance Global Partners as the sales agent. The common stock is traded on the Nasdaq Capital Market under the symbol 'PCSA.' The offering will be made as an 'at the market offering,' allowing the sale of shares from time to time at prevailing market prices. Processa intends to use the net proceeds for continued research and development of its drug candidates, particularly its oncology products, as well as for working capital and general corporate purposes. The company has not disclosed the number of shares to be offered or the price range for the offering. As of May 17, 2024, the closing price of Processa's common stock was $1.96 per share.

Processa Pharmaceuticals, Inc. has filed a registration statement with the Securities and Exchange Commission (SEC) on May 21, 2024, for a proposed public offering of its common stock. The company, incorporated in Delaware and based in Hanover, Maryland, plans to offer up to $2,400,000 of its common stock through A.G.P./Alliance Global Partners as the sales agent. The common stock is traded on the Nasdaq Capital Market under the symbol 'PCSA.' The offering will be made as an 'at the market offering,' allowing the sale of shares from time to time at prevailing market prices. Processa intends to use the net proceeds for continued research and development of its drug candidates, particularly its oncology products, as well as for working capital and general corporate purposes. The company has not disclosed the number of shares to be offered or the price range for the offering. As of May 17, 2024, the closing price of Processa's common stock was $1.96 per share.